Outcome of the board meeting and submission of the audited standalone finaacial results for the half year and year ended march 31, 2026 and appointment of internal auditor.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shelter Pharma Limited reported audited standalone financial results for FY 2025-26 (year ended March 31, 2026). Revenue from operations grew 44.4% to Rs. 7,313.36 lakhs from Rs. 5,066.02 lakhs in the previous year. Profit after tax increased 24.75% to Rs. 902.72 lakhs from Rs. 723.74 lakhs. EPS stood at Rs. 6.57. However, operating cash flow turned significantly negative at Rs. -1,248.01 lakhs compared to positive Rs. 542.28 lakhs in the prior year, primarily due to large increases in inventories (Rs. 1,154.37 lakhs) and short-term loans and advances (Rs. 1,067.81 lakhs). The statutory auditor issued an unmodified (clean) opinion. The company also raised Rs. 2,531.20 lakhs through preferential issue of convertible warrants for working capital. CA Ismail Ibrahimbhai Lakhani was appointed as internal auditor for FY 2026-27.
Strong revenue and profit growth with clean audit is positive; however, the significant negative operating cash flow despite profit growth raises concerns about earnings quality and working capital management, which could be a red flag for investors.